Precigen Shares Higher After Leukemia Fast Track Designation
April 04 2022 - 8:58AM
Dow Jones News
By Michael Dabaie
Precigen Inc. shares were up 12% to $2.55 in premarket trade
Monday after the U.S. Food and Drug Administration granted fast
track designation for PRGN-3006 UltraCAR-T in acute myeloid
leukemia.
The company said it was granted the designation for PRGN-3006
UltraCAR-T in patients with relapsed or refractory AML. Precigen
said AML is among the most common types of leukemia in adults. AML
is a cancer that starts in the bone marrow, but most often moves
into the blood.
FDA previously granted PRGN-3006 orphan drug designation.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
April 04, 2022 08:43 ET (12:43 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Precigen (NASDAQ:PGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Precigen (NASDAQ:PGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024